Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 20 studies | 42% ± 24% | |
smooth muscle cell | 17 studies | 42% ± 21% | |
fibroblast | 17 studies | 30% ± 19% | |
astrocyte | 16 studies | 36% ± 16% | |
mast cell | 12 studies | 36% ± 19% | |
endothelial cell | 8 studies | 38% ± 16% | |
adipocyte | 7 studies | 32% ± 14% | |
oligodendrocyte precursor cell | 7 studies | 23% ± 5% | |
interneuron | 6 studies | 38% ± 20% | |
cardiac muscle cell | 6 studies | 83% ± 16% | |
glutamatergic neuron | 5 studies | 28% ± 9% | |
myofibroblast cell | 5 studies | 24% ± 6% | |
GABAergic neuron | 5 studies | 30% ± 12% | |
granule cell | 4 studies | 35% ± 14% | |
retina horizontal cell | 4 studies | 65% ± 13% | |
mesothelial cell | 4 studies | 57% ± 30% | |
endocardial cell | 3 studies | 36% ± 9% | |
GABAergic amacrine cell | 3 studies | 73% ± 16% | |
amacrine cell | 3 studies | 71% ± 14% | |
glycinergic amacrine cell | 3 studies | 48% ± 12% | |
retinal ganglion cell | 3 studies | 36% ± 15% | |
rod bipolar cell | 3 studies | 61% ± 27% | |
muscle cell | 3 studies | 50% ± 29% | |
neural progenitor cell | 3 studies | 44% ± 11% | |
ependymal cell | 3 studies | 34% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 85% | 1207.23 | 278 / 328 | 81% | 6.46 | 145 / 178 |
intestine | 99% | 5088.91 | 955 / 966 | 65% | 5.42 | 342 / 527 |
prostate | 71% | 1547.07 | 173 / 245 | 82% | 5.93 | 412 / 502 |
ovary | 64% | 1055.13 | 116 / 180 | 83% | 8.14 | 357 / 430 |
lung | 84% | 1347.63 | 484 / 578 | 46% | 4.15 | 535 / 1155 |
breast | 81% | 1376.16 | 374 / 459 | 47% | 2.27 | 526 / 1118 |
uterus | 91% | 1680.56 | 155 / 170 | 36% | 4.11 | 165 / 459 |
esophagus | 64% | 4448.32 | 931 / 1445 | 60% | 4.75 | 110 / 183 |
stomach | 42% | 1618.59 | 151 / 359 | 71% | 6.28 | 203 / 286 |
kidney | 44% | 612.03 | 39 / 89 | 60% | 5.88 | 541 / 901 |
thymus | 70% | 1000.35 | 456 / 653 | 33% | 1.16 | 197 / 605 |
blood vessel | 100% | 9241.11 | 1335 / 1335 | 0% | 0 | 0 / 0 |
adipose | 97% | 2205.24 | 1170 / 1204 | 0% | 0 | 0 / 0 |
heart | 97% | 8292.61 | 833 / 861 | 0% | 0 | 0 / 0 |
brain | 17% | 215.12 | 448 / 2642 | 63% | 2.92 | 446 / 705 |
bladder | 48% | 704.52 | 10 / 21 | 28% | 1.94 | 143 / 504 |
adrenal gland | 0% | 3.16 | 1 / 258 | 63% | 7.99 | 145 / 230 |
skin | 11% | 128.86 | 191 / 1809 | 51% | 6.63 | 243 / 472 |
eye | 0% | 0 | 0 / 0 | 61% | 8.43 | 49 / 80 |
liver | 2% | 20.18 | 5 / 226 | 23% | 1.35 | 92 / 406 |
spleen | 23% | 270.45 | 56 / 241 | 0% | 0 | 0 / 0 |
muscle | 14% | 146.06 | 110 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 9% | 0.31 | 4 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019934 | Biological process | cGMP-mediated signaling |
GO_0097190 | Biological process | apoptotic signaling pathway |
GO_0071560 | Biological process | cellular response to transforming growth factor beta stimulus |
GO_0043116 | Biological process | negative regulation of vascular permeability |
GO_0019933 | Biological process | cAMP-mediated signaling |
GO_0071321 | Biological process | cellular response to cGMP |
GO_0001556 | Biological process | oocyte maturation |
GO_0060700 | Biological process | regulation of ribonuclease activity |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0040020 | Biological process | regulation of meiotic nuclear division |
GO_0043401 | Biological process | steroid hormone receptor signaling pathway |
GO_0060282 | Biological process | positive regulation of oocyte development |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0043951 | Biological process | negative regulation of cAMP-mediated signaling |
GO_0006629 | Biological process | lipid metabolic process |
GO_0106072 | Biological process | negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway |
GO_0043117 | Biological process | positive regulation of vascular permeability |
GO_0016020 | Cellular component | membrane |
GO_0005829 | Cellular component | cytosol |
GO_0004114 | Molecular function | 3',5'-cyclic-nucleotide phosphodiesterase activity |
GO_0099130 | Molecular function | estrogen binding |
GO_0004119 | Molecular function | cGMP-inhibited cyclic-nucleotide phosphodiesterase activity |
GO_0047555 | Molecular function | 3',5'-cyclic-GMP phosphodiesterase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0004115 | Molecular function | 3',5'-cyclic-AMP phosphodiesterase activity |
GO_0005515 | Molecular function | protein binding |
GO_0030284 | Molecular function | nuclear estrogen receptor activity |
Gene name | PDE3A |
Protein name | cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (EC 3.1.4.17) (Cyclic GMP-inhibited phosphodiesterase A) (CGI-PDE A) (cGMP-inhibited cAMP phosphodiesterase) (cGI-PDE) |
Synonyms | |
Description | FUNCTION: Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes . Has also activity toward cUMP . Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway. E2 stabilizes the PDE3A/SLFN12 complex in the cytosol, promoting the dephosphorylation of SLFN12 and activating its pro-apoptotic ribosomal RNA/rRNA ribonuclease activity. This apoptotic pathway might be relevant in tissues with high concentration of E2 and be for instance involved in placenta remodeling . . |
Accessions | ENST00000359062.4 Q14432 |